Partial agonists activate PPARgamma using a helix 12 independent mechanism.

Binding to helix 12 of the ligand-binding domain of PPARgamma is required for full agonist activity. Previously, the degree of stabilization of the activation function 2 (AF-2) surface was thought to correlate with the degree of agonism and transactivation. To examine this mechanism, we probed structural dynamics of PPARgamma with agonists that induced graded transcriptional responses. Here we present crystal structures and amide H/D exchange (HDX) kinetics for six of these complexes. Amide HDX revealed each ligand induced unique changes to the dynamics of the ligand-binding domain (LBD). Full agonists stabilized helix 12, whereas intermediate and partial agonists did not at all, and rather differentially stabilized other regions of the binding pocket. The gradient of PPARgamma transactivation cannot be accounted for solely through changes to the dynamics of AF-2. Thus, our understanding of allosteric signaling must be extended beyond the idea of a dynamic helix 12 acting as a molecular switch.

[1]  J. Berger,et al.  PPARs: therapeutic targets for metabolic disease. , 2005, Trends in pharmacological sciences.

[2]  J. Berger,et al.  Physiological and therapeutic roles of peroxisome proliferator-activated receptors. , 2002, Diabetes technology & therapeutics.

[3]  M. Deinzer,et al.  Dynamics and ligand-induced solvent accessibility changes in human retinoid X receptor homodimer determined by hydrogen deuterium exchange and mass spectrometry. , 2004, Biochemistry.

[4]  T. Willson,et al.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ1 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Kendall W Nettles,et al.  Ligand control of coregulator recruitment to nuclear receptors. , 2005, Annual review of physiology.

[6]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[7]  R. Evans,et al.  Mechanism of corepressor binding and release from nuclear hormone receptors. , 1999, Genes & development.

[8]  J. Auwerx,et al.  A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.

[9]  R G Smith,et al.  Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. , 2000, Journal of molecular biology.

[10]  T. Fujimura,et al.  FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. , 2005, Journal of pharmacological sciences.

[11]  Joel P. Berger,et al.  Benzoyl 2-methyl indoles as selective PPARγ modulators , 2005 .

[12]  Scott A. Busby,et al.  The Deuterator: software for the determination of backbone amide deuterium levels from H/D exchange MS data , 2007, BMC Bioinformatics.

[13]  J. Gustafsson,et al.  Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Armin Ruf,et al.  A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro , 2006 .

[15]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[16]  J. Clapham,et al.  The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats. , 1996, Biochemical and biophysical research communications.

[17]  Greene,et al.  Rosiglitazone: a new therapy for Type 2 diabetes. , 1999, Expert opinion on investigational drugs.

[18]  L. Jendeberg,et al.  A New Class of Peroxisome Proliferator-activated Receptor Agonists with a Novel Binding Epitope Shows Antidiabetic Effects* , 2004, Journal of Biological Chemistry.

[19]  J. Schwabe,et al.  Mechanism of the nuclear receptor molecular switch. , 2004, Trends in biochemical sciences.

[20]  T. Fujimura,et al.  Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. , 2006, Biological & pharmaceutical bulletin.

[21]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[22]  F. Collart,et al.  A new vector for high-throughput, ligation-independent cloning encoding a tobacco etch virus protease cleavage site. , 2002, Protein expression and purification.

[23]  I-Lin Lu,et al.  Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities. , 2005, Journal of medicinal chemistry.

[24]  L. Jendeberg,et al.  Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ* , 1998, The Journal of Biological Chemistry.

[25]  C. Day.  Thiazolidinediones: a new class of antidiabetic drugs , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[26]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[27]  M. Lazar,et al.  The Dawn of the SPPARMs? , 2002, Science's STKE.

[28]  S. Englander.  Hydrogen exchange and mass spectrometry: A historical perspective , 2006, Journal of the American Society for Mass Spectrometry.

[29]  Ingrid Pettersson,et al.  Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity , 2002 .

[30]  Bruce A. Johnson,et al.  Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.

[31]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[32]  D. Moras,et al.  Biochemical and NMR Mapping of the Interface between CREB-binding Protein and Ligand Binding Domains of Nuclear Receptor , 2005, Journal of Biological Chemistry.

[33]  J. Fleckner,et al.  Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. , 2003, Journal of medicinal chemistry.

[34]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[35]  J. Berger,et al.  L-764406 Is a Partial Agonist of Human Peroxisome Proliferator-activated Receptor γ , 1999, The Journal of Biological Chemistry.

[36]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[37]  S. Tuske,et al.  Hydrogen/deuterium‐exchange (H/D‐Ex) of PPARγ LBD in the presence of various modulators , 2006, Protein science : a publication of the Protein Society.

[38]  Claudia S Maier,et al.  Protein conformations, interactions, and H/D exchange. , 2005, Methods in enzymology.

[39]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[40]  Zhengshuang Shi,et al.  Networks for the allosteric control of protein kinases. , 2006, Current opinion in structural biology.

[41]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[42]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[43]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[44]  J. Lehmann,et al.  A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Schwabe,et al.  A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease , 2003, Nature Structural Biology.

[46]  Scott A. Busby,et al.  Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. , 2006, Analytical chemistry.

[47]  C. Glass,et al.  Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. , 2006, Genes & development.